A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer is a research paper published in Scientific Reports (2021). On theSindex it has a DataRank of 0. It has been cited 23 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NIH/NCI through the Cancer Center Support Grant of The University of Texas MD Anderson Cancer Center
Grant: CA016672
NCI NIH HHS
Grant: P30 CA016672
the Morgan Welch Inflammatory Breast Cancer Research Program; a State of Texas Rare and Aggressive Breast Cancer Research Program Grant
Amgen
MeSH Terms